Condition: Urinary Incontinence in Children · Sponsor: University of Aarhus
The primary objective is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose. In total, 236 children diagnosed with daytime urinary incontinence will be randomized 1:1:1:1 to one of four treatment groups. Total pharmacological treatment period will be 18 weeks.
This description comes directly from the study's public registry record.
Ann-Kristine Mandøe Svendsen, MD · +45 78430408 · ankrso@rm.dk
Luise Borch, MD, PhD · +45 78433654 · luiseborch@rm.dk
Always discuss trial participation with your own doctor first.
| Department of Pediatric and Adolescent Medicine, Aalborg University Hospital | Aalborg, Aalborg, Denmark | Recruiting |
| Department of Pediatric and Adolescent Medicine, Aarhus University Hospital | Aarhus, Aarhus N, Denmark | Recruiting |
| Department of Pediatric and Adolescent medicine, Esbjerg Hospital | Esbjerg, Esbjerg, Denmark | Recruiting |
| Department of Pediatric and Adolescent Medicine, Gødstrup Hospital | Herning, Herning, Denmark | Recruiting |
| Department of Pediatric and Adolescent Medicine, Kolding Hospital | Kolding, Kolding, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06551246